Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Obstetricia y Ginecología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Reclutando
ClinicalTrials.gov
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
OBSERVATIONAL
Inicio: 20 de dic de 2025
ID: NCT06717295
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)
INTERVENTIONAL
Inicio: 18 de ene de 2024
ID: NCT06018337
Terminado
ClinicalTrials.gov
Conservative Surgery for Women With Low-Risk, Early Stage Cervical Cancer
INTERVENTIONAL
Inicio: 15 de abr de 2010
ID: NCT01048853
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)
INTERVENTIONAL
Inicio: 25 de oct de 2018
ID: NCT03635567
Completado
Fase 3
ClinicalTrials.gov
A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination With Trastuzumab and Paclitaxel, as First Line Therapy in Women With HER2 Positive Locally Advanced or Metastatic Breast Cancer
INTERVENTIONAL
Inicio: 10 de sept de 2009
ID: NCT00876395
Reclutando
Fase 3
ClinicalTrials.gov
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)
INTERVENTIONAL
Inicio: 21 de jul de 2025
ID: NCT07060807
Completado
Fase 2
ClinicalTrials.gov
A Phase II Open-label, Randomized, Three-arm, Multicenter Study of LAG525 Given in Combination With Spartalizumab (PDR001), or With Spartalizumab and Carboplatin, or With Carboplatin, as First or Second Line Therapy in Patients With Advanced Triple-negative Breast Cancer
INTERVENTIONAL
Inicio: 2 de jul de 2018
ID: NCT03499899
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
INTERVENTIONAL
Inicio: 29 de ene de 2020
ID: NCT04191499
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer
INTERVENTIONAL
Inicio: 27 de ago de 2021
ID: NCT04961996
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)
INTERVENTIONAL
Inicio: 16 de nov de 2023
ID: NCT06016738
Activo, no recluta
ClinicalTrials.gov
A STUDY TO OBSERVE PATIENTS CHARACTERISTICS, TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED BREAST CANCER IN LATIN AMERICA
OBSERVATIONAL
Inicio: 21 de feb de 2020
ID: NCT04158258
Completado
ClinicalTrials.gov
Study of HPV Self Testing Evaluation in the Province of Jujuy, Argentina
INTERVENTIONAL
Inicio: 1 de jul de 2012
ID: NCT02095561
Completado
Fase 3
ClinicalTrials.gov
STUDY OF PALBOCICLIB IN COMBINATION WITH LETROZOLE AS TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER FOR WHOM LETROZOLE THERAPY IS DEEMED APPROPRIATE
INTERVENTIONAL
Inicio: 15 de abr de 2016
ID: NCT02600923
Terminado
ClinicalTrials.gov
International Multi-center, Randomized and Controlled Clinical Study, to Evaluate the Clinical Benefit of the ERA Test in Infertile Patients Undergoing Assisted Reproduction Treatment and Medical Indication of PGT-A.
INTERVENTIONAL
Inicio: 28 de may de 2018
ID: NCT03530254
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
INTERVENTIONAL
Inicio: 18 de nov de 2019
ID: NCT04109066
Completado
ClinicalTrials.gov
Mixed-Methods Approach to Evaluate a mHealth Intervention to Increase Adherence to Triage of HPV+ Women Who Have Performed Self-collection
INTERVENTIONAL
Inicio: 5 de dic de 2018
ID: NCT03478397
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
INTERVENTIONAL
Inicio: 10 de ene de 2021
ID: NCT04634877
Completado
Fase 3
ClinicalTrials.gov
A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide (TAC) Versus 5-fluorouracil in Combination With Doxorubicin and Cyclophosphamide (FAC) as Adjuvant Treatment of Operable Breast Cancer Patients With Positive Axillary Lymph Nodes.
INTERVENTIONAL
Inicio: 1 de jun de 1997
ID: NCT00688740
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
INTERVENTIONAL
Inicio: 9 de oct de 2020
ID: NCT04546009
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02)
INTERVENTIONAL
Inicio: 16 de may de 2022
ID: NCT05374512
Anterior
1
...
5
6
7
...
434
Siguiente
Filtros